Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to ...
Wednesday, April 1, 2026 – Thursday, April 2 - Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard protocol and may undermine weight-loss results.
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a ...
Wednesday, April 1, 2026 – Thursday, April 2 - While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
Tuesday, March 31, 2026 – Wednesday, April 1 - INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited.
Across 60 meta-analyses that assessed 116 non...
Tuesday, March 31, 2026 – TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for major adverse cardiovascular events, according to a study published online...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- The PREVENT-TAHA8 intracoronary stem cell trial from Iran was officially retracted by The BMJ, months after an expression of concern was first published.
Poor diet remains a leading contributor to ischemic heart disease, with...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)...